MAP Kinase Signaling

p44/42 MAPK (Erk1/2) Blocking Peptide (#4696 Specific)

イイネ！(0)
CSTコード 包装
希望納入価格 (円)
国内在庫 i
2012年2月3日18時20分 現在
ご登録代理店情報 i
カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更はこちら。
#1245S100 μg16,000
ログインすると国内在庫状況がご確認いただけます。

MAPK抗体製品一覧

用途
免疫組織染色
貯法
-20℃
使用目的
p44/42 MAPK (L34F12) Mouse mAb （#4696）の反応をブロックし、抗体の反応特異性を確認するために使用
社内データ

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb #4696 in the presence of control peptide (left) or p44/42 MAPK (Erk1/2) Blocking Peptide (#4696 Specific) (right).

バックグラウンド

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059.

  1. Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
  2. Baccarini, M. (2005) FEBS Lett 579, 3271-7.
  3. Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39.
  4. Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.
  5. Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.
  6. Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.
  7. Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
  8. Marais, R. et al. (1993) Cell 73, 381-93.
  9. Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
  10. Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.
使用例
製品をご使用いただいて研究を発表されましたら、ぜひお知らせください。
 
関連製品
4696   p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb
8103   SignalSlide® Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Controls

本製品は試験研究用です。

p44/42 MAPK (Erk1/2) Blocking Peptide (#4696 Specific)

Product Pathways

Tools

Applications